Parkinson disease
Conditions
Interventions
Prescription istradefylline 20 mg for 1 month. If there are no side effects, We increase to 40 mg and prescribe for 2 months. The assessments will be made in all patients participating the study, pat
Sponsors
Ichinomiya Nishi Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. The patients meet clinically established or clinically probable cases of clinical diagnostic criteria of Parkinson disease by Movement Disorder Society 2. The item of Attention/memory in NMSS is 1 or more. 3. The patient is treated with drugs that include L-dopa 4. The age of patients is 40 to 85years old. 5. Written consent has been obtained.
Exclusion criteria
Exclusion criteria: 1. Mini mental state examination (MMSE) is 20 points or less. 2. Istradefylline has been prescribed
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary outcome is digit span test, arithmetic test, verval fluency test, Standard verbal paired-associate learning test, Benton visual retention test. These tests will be evaluated 12weeks later after starting treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcomes are Movement Disorder Society-Unified Parkinson Disease Rating Scale(MDS-UPDRS),mini-mental state examination(MMSE), Non-motor symptoms scales and freezing of gait of questionnaire(FOG-Q). | — |
Countries
Japan
Contacts
Public ContactMasahiro Kanai
Ichinomiya Nishi Hospital Neurology
Outcome results
None listed